Urinary excretion of valproate metabolites in children and adolescents
The objective of this communication is to describe the changes in the metabolic profile of valproic acid (VPA) from early to late childhood and adolescence. A cross‐sectional study of 12 children and adolescents attending a neurological outpatients department, who were medicated with VPA, was carrie...
Gespeichert in:
| Veröffentlicht in: | Biopharmaceutics & drug disposition 2000-11, Vol.21 (8), p.327-330 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 330 |
|---|---|
| container_issue | 8 |
| container_start_page | 327 |
| container_title | Biopharmaceutics & drug disposition |
| container_volume | 21 |
| creator | Reith, David M. Andrews, Jaymie Parker-Scott, Suzie Eadie, Mervyn J. |
| description | The objective of this communication is to describe the changes in the metabolic profile of valproic acid (VPA) from early to late childhood and adolescence. A cross‐sectional study of 12 children and adolescents attending a neurological outpatients department, who were medicated with VPA, was carried out. The proportions of daily dose excreted as VPA‐glucuronide, 3‐oxo‐VPA and 4‐OH‐VPA were calculated by relating 24‐h recovery of these metabolites from urine to daily VPA dose. VPA, 3‐oxo‐VPA and 2‐en‐valproic acid (2‐en‐VPA) were measured in trough serum samples. VPA and its metabolites were measured using a capillary gas chromatograpy method. The proportion of daily dose recovered as VPA‐glucuronide in children 10 years and younger was smaller than in older children (p |
| doi_str_mv | 10.1002/bdd.247 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_bdd_247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_SSGWHWQ6_Z</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3807-cbdff7496b95fc7fd130666e943558e7220102f2df73ae65e9cb84c8a327e4a23</originalsourceid><addsrcrecordid>eNp10M9LwzAUB_Agis4p_gfSg-BBqvnRJu1RN7cJosgcEy8hTV4w2rUjqbr991Y61Iund_nwvu99EToi-JxgTC8KY85pIrZQj-A8j3FGnrZRD5OExlRkdA_th_CKMeaEkF20R0hKkjylPTSaeVcpv45gpT00rq6i2kYfqlz6WjUQLaBRRV26BkLkqki_uNJ4qCJVmUiZuoSgoWrCAdqxqgxwuJl9NBtdPw4m8e39-GZweRtrlmER68JYK5KcF3lqtbCGMMw5hzxhaZqBoBQTTC01VjAFPIVcF1miM8WogERR1ken3V7t6xA8WLn0btHeLwmW303ItgnZNtHK404u34sFmF-3eb0FJxugglal9arSLvzZlzPOScvOOvbpSlj_FyevhsMuNe60Cw2sfrTyb5ILJlI5vxvL6XQ8n8wfuHxmX0aJgws</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Urinary excretion of valproate metabolites in children and adolescents</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Reith, David M. ; Andrews, Jaymie ; Parker-Scott, Suzie ; Eadie, Mervyn J.</creator><creatorcontrib>Reith, David M. ; Andrews, Jaymie ; Parker-Scott, Suzie ; Eadie, Mervyn J.</creatorcontrib><description>The objective of this communication is to describe the changes in the metabolic profile of valproic acid (VPA) from early to late childhood and adolescence. A cross‐sectional study of 12 children and adolescents attending a neurological outpatients department, who were medicated with VPA, was carried out. The proportions of daily dose excreted as VPA‐glucuronide, 3‐oxo‐VPA and 4‐OH‐VPA were calculated by relating 24‐h recovery of these metabolites from urine to daily VPA dose. VPA, 3‐oxo‐VPA and 2‐en‐valproic acid (2‐en‐VPA) were measured in trough serum samples. VPA and its metabolites were measured using a capillary gas chromatograpy method. The proportion of daily dose recovered as VPA‐glucuronide in children 10 years and younger was smaller than in older children (p<0.05). There were no differences between age groups in the recovery of the other measured metabolites. Lamotrigine (LTG) comedication was also associated with a higher proportion of VPA dose recovered as glucuronide (p<0.01). LTG comedication had a stronger association with a higher proportion of dose being recovered as VPA‐glucuronide on multivariate analysis than did the age group (p=0.001 versus p<0.05). In conclusion, older children and adolescents, when compared with younger children, and those comedicated with LTG excrete a higher proportion of VPA dose as VPA‐glucuronide. Copyright © 2000 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0142-2782</identifier><identifier>EISSN: 1099-081X</identifier><identifier>DOI: 10.1002/bdd.247</identifier><identifier>PMID: 11514952</identifier><identifier>CODEN: BDDID8</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adolescent ; Aging - metabolism ; Anticonvulsants - urine ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Biological and medical sciences ; Biotransformation ; Child ; Child, Preschool ; Chromatography, Gas ; Cross-Sectional Studies ; Drug Combinations ; Drug Interactions ; Female ; Humans ; Hydrolysis ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Triazines - pharmacokinetics ; Valproic Acid - urine</subject><ispartof>Biopharmaceutics & drug disposition, 2000-11, Vol.21 (8), p.327-330</ispartof><rights>Copyright © 2000 John Wiley & Sons, Ltd.</rights><rights>2001 INIST-CNRS</rights><rights>Copyright 2000 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3807-cbdff7496b95fc7fd130666e943558e7220102f2df73ae65e9cb84c8a327e4a23</citedby><cites>FETCH-LOGICAL-c3807-cbdff7496b95fc7fd130666e943558e7220102f2df73ae65e9cb84c8a327e4a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fbdd.247$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbdd.247$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1093661$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11514952$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reith, David M.</creatorcontrib><creatorcontrib>Andrews, Jaymie</creatorcontrib><creatorcontrib>Parker-Scott, Suzie</creatorcontrib><creatorcontrib>Eadie, Mervyn J.</creatorcontrib><title>Urinary excretion of valproate metabolites in children and adolescents</title><title>Biopharmaceutics & drug disposition</title><addtitle>Biopharm. Drug Dispos</addtitle><description>The objective of this communication is to describe the changes in the metabolic profile of valproic acid (VPA) from early to late childhood and adolescence. A cross‐sectional study of 12 children and adolescents attending a neurological outpatients department, who were medicated with VPA, was carried out. The proportions of daily dose excreted as VPA‐glucuronide, 3‐oxo‐VPA and 4‐OH‐VPA were calculated by relating 24‐h recovery of these metabolites from urine to daily VPA dose. VPA, 3‐oxo‐VPA and 2‐en‐valproic acid (2‐en‐VPA) were measured in trough serum samples. VPA and its metabolites were measured using a capillary gas chromatograpy method. The proportion of daily dose recovered as VPA‐glucuronide in children 10 years and younger was smaller than in older children (p<0.05). There were no differences between age groups in the recovery of the other measured metabolites. Lamotrigine (LTG) comedication was also associated with a higher proportion of VPA dose recovered as glucuronide (p<0.01). LTG comedication had a stronger association with a higher proportion of dose being recovered as VPA‐glucuronide on multivariate analysis than did the age group (p=0.001 versus p<0.05). In conclusion, older children and adolescents, when compared with younger children, and those comedicated with LTG excrete a higher proportion of VPA dose as VPA‐glucuronide. Copyright © 2000 John Wiley & Sons, Ltd.</description><subject>Adolescent</subject><subject>Aging - metabolism</subject><subject>Anticonvulsants - urine</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Biological and medical sciences</subject><subject>Biotransformation</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chromatography, Gas</subject><subject>Cross-Sectional Studies</subject><subject>Drug Combinations</subject><subject>Drug Interactions</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrolysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Triazines - pharmacokinetics</subject><subject>Valproic Acid - urine</subject><issn>0142-2782</issn><issn>1099-081X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M9LwzAUB_Agis4p_gfSg-BBqvnRJu1RN7cJosgcEy8hTV4w2rUjqbr991Y61Iund_nwvu99EToi-JxgTC8KY85pIrZQj-A8j3FGnrZRD5OExlRkdA_th_CKMeaEkF20R0hKkjylPTSaeVcpv45gpT00rq6i2kYfqlz6WjUQLaBRRV26BkLkqki_uNJ4qCJVmUiZuoSgoWrCAdqxqgxwuJl9NBtdPw4m8e39-GZweRtrlmER68JYK5KcF3lqtbCGMMw5hzxhaZqBoBQTTC01VjAFPIVcF1miM8WogERR1ken3V7t6xA8WLn0btHeLwmW303ItgnZNtHK404u34sFmF-3eb0FJxugglal9arSLvzZlzPOScvOOvbpSlj_FyevhsMuNe60Cw2sfrTyb5ILJlI5vxvL6XQ8n8wfuHxmX0aJgws</recordid><startdate>200011</startdate><enddate>200011</enddate><creator>Reith, David M.</creator><creator>Andrews, Jaymie</creator><creator>Parker-Scott, Suzie</creator><creator>Eadie, Mervyn J.</creator><general>John Wiley & Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200011</creationdate><title>Urinary excretion of valproate metabolites in children and adolescents</title><author>Reith, David M. ; Andrews, Jaymie ; Parker-Scott, Suzie ; Eadie, Mervyn J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3807-cbdff7496b95fc7fd130666e943558e7220102f2df73ae65e9cb84c8a327e4a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Aging - metabolism</topic><topic>Anticonvulsants - urine</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Biological and medical sciences</topic><topic>Biotransformation</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chromatography, Gas</topic><topic>Cross-Sectional Studies</topic><topic>Drug Combinations</topic><topic>Drug Interactions</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrolysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Triazines - pharmacokinetics</topic><topic>Valproic Acid - urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reith, David M.</creatorcontrib><creatorcontrib>Andrews, Jaymie</creatorcontrib><creatorcontrib>Parker-Scott, Suzie</creatorcontrib><creatorcontrib>Eadie, Mervyn J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Biopharmaceutics & drug disposition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reith, David M.</au><au>Andrews, Jaymie</au><au>Parker-Scott, Suzie</au><au>Eadie, Mervyn J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary excretion of valproate metabolites in children and adolescents</atitle><jtitle>Biopharmaceutics & drug disposition</jtitle><addtitle>Biopharm. Drug Dispos</addtitle><date>2000-11</date><risdate>2000</risdate><volume>21</volume><issue>8</issue><spage>327</spage><epage>330</epage><pages>327-330</pages><issn>0142-2782</issn><eissn>1099-081X</eissn><coden>BDDID8</coden><abstract>The objective of this communication is to describe the changes in the metabolic profile of valproic acid (VPA) from early to late childhood and adolescence. A cross‐sectional study of 12 children and adolescents attending a neurological outpatients department, who were medicated with VPA, was carried out. The proportions of daily dose excreted as VPA‐glucuronide, 3‐oxo‐VPA and 4‐OH‐VPA were calculated by relating 24‐h recovery of these metabolites from urine to daily VPA dose. VPA, 3‐oxo‐VPA and 2‐en‐valproic acid (2‐en‐VPA) were measured in trough serum samples. VPA and its metabolites were measured using a capillary gas chromatograpy method. The proportion of daily dose recovered as VPA‐glucuronide in children 10 years and younger was smaller than in older children (p<0.05). There were no differences between age groups in the recovery of the other measured metabolites. Lamotrigine (LTG) comedication was also associated with a higher proportion of VPA dose recovered as glucuronide (p<0.01). LTG comedication had a stronger association with a higher proportion of dose being recovered as VPA‐glucuronide on multivariate analysis than did the age group (p=0.001 versus p<0.05). In conclusion, older children and adolescents, when compared with younger children, and those comedicated with LTG excrete a higher proportion of VPA dose as VPA‐glucuronide. Copyright © 2000 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>11514952</pmid><doi>10.1002/bdd.247</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0142-2782 |
| ispartof | Biopharmaceutics & drug disposition, 2000-11, Vol.21 (8), p.327-330 |
| issn | 0142-2782 1099-081X |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_bdd_247 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Adolescent Aging - metabolism Anticonvulsants - urine Anticonvulsants. Antiepileptics. Antiparkinson agents Biological and medical sciences Biotransformation Child Child, Preschool Chromatography, Gas Cross-Sectional Studies Drug Combinations Drug Interactions Female Humans Hydrolysis Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Triazines - pharmacokinetics Valproic Acid - urine |
| title | Urinary excretion of valproate metabolites in children and adolescents |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T13%3A56%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20excretion%20of%20valproate%20metabolites%20in%20children%20and%20adolescents&rft.jtitle=Biopharmaceutics%20&%20drug%20disposition&rft.au=Reith,%20David%20M.&rft.date=2000-11&rft.volume=21&rft.issue=8&rft.spage=327&rft.epage=330&rft.pages=327-330&rft.issn=0142-2782&rft.eissn=1099-081X&rft.coden=BDDID8&rft_id=info:doi/10.1002/bdd.247&rft_dat=%3Cistex_cross%3Eark_67375_WNG_SSGWHWQ6_Z%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11514952&rfr_iscdi=true |